Student Directory

Zainul Hasanali

Class Year: M3



  • M.D./Ph.D. Program


Contact Information:


Biographical Information:

Hometown: Tomball, TX



Undergraduate Education:  BS/09 Chemistry/Boston


Research Interests:

Research Interest:  Focuses on studying epigenetic modifications in T-cell leukemias and the potential to overcome therapeutic resistance through the use of drugs that modify the epigenome.

Advisor: Thomas Loughran, MD/Elliot Epner, MD
Graduate Program: Molecular Medicine
Thesis: (title tba)

Description:  studying the effects of vorinostat and cladribine as histone deacetylase inhibitors and methyltransferase inhibitors, respectively, in T-cell prolymphocytic leukemia (T-PLL) and large granular lymphocytic leukemia (T-LGL).  Specifically, I am focusing on their effect on and the role of the tribbles1 pseudokinase in the regulation of MAPK pathway activation in order to better understand the highly aggressive growth pattern of T-PLL and gain insight into the normal biology of tribbles1 and its role in cell growth and survival. Tribbles1 is a scaffod protein that has the ability to ubiquinate CEBP transcription factors and to bind downstream MAPK signalling proteins such as MEK and ERK, making it well suited to regulate mitogen signalling.  Its function is complex.  Indeed, both  over and under expression of tribbles1 has been shown to contribute to leukemogenesis.  In line with this, we have observed low levels of tribbles1 in T-PLL and high levels in T-LGL, providing support to the theory that scaffold protein concentrations must be maintained at defined levels to be effective.

Meeting Presentations

  • 2011
    ASH annual meeting, San Diego, CA (poster)
  • 2012
    ASCO annual meeting, Chicago, IL (poster)
    American Society of Hematology annual meeting, Atlanta, GA (poster)
  • 2013
    AACR annual meeting, Washington D.C. (poster) *did not attend but sent poster
    Penn State College of Medicine Graduate Research Forum, Hershey, PA (poster)
  • 2014
    Lindau Meeting of Nobel Laureates in Lindau, Germany
    Herpes Viruses:  Pathogenesis & Cancer Symposium, Philadelphia, Pa



Zhao HZ, Zhou S, Hasanali Z, et al (2008) Influence of Pressure on Silicon Nanowire Growth Kinetics  J of Physical Chem C 112(15): 5695-98  PMCID:  (no number)

Yuan G, Zhao H, Liu X, Hasanali ZS, Zou Y, Levine A, Wang D (2009) Synthesis and photoelectrochemical study of vertically aligned silicon nanowire arrays Angew Chem Int Ed Engl 48(51):9680-4  PMCID:  (no number)

Hasanali Z, Sharma K, Epner E (2012) Flipping the cyclin D1 switch in mantle cell lymphoma Best Pract Res Clin Haematol 25(2):143-152  PMCID:  (no number)

Hasanali Z, Stuart A, Nelson Y, Sharma K, Epner E (2012) The Epigenetics of Gastrointestinal Malignancies Current Colorectal Cancer Reports 8(4):254-62  PMCID:  (no number)

LeBlanc FR, Hasanali ZS, Loughran TP Jr. (2013) Does IL-15 have a causative role in large granular lymphocyte leukemia? Immunotherapy 5(3):231-4  PMCID:  (no number)

Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, Roussel M, Fest T, Awwad A, Baab K, Semenzato G, Houot R, Loughran TP Jr, Lamy T (2013) Cyclophosphamide as a first-line therapy in LGL leukemia Leukemia 28(5):1134-6  PMCID:  PMC4017255

Sun X, Hasanali Z, Chen A, Zhang D, Liu X, Wang HG, Feith D, Loughran TP, Xu K (2014) SAHA and cladribine synergistically induce apoptosis in NK-LGL leukemia British J of Haematology (in press)

Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS (2014) Immunosupressive therapy of LGL leukemia:  prospective multicenter phase II study by the eastern cooperative oncoogy group (E5998) Leukemia [Epub ahead of print]

Hasanali ZS, Epner EM, Feith DJ, Loughran TP Jr, Sample CE (2014) Vorinostat Downregulates CD30 and Decreases Brentuximab Vedotin Efficacy in Human Lymphocytes Mol Cancer Ther [Epub ahead of print]




Zainul Hasanali


Related Links:


Media interested in contacting the above person should contact the Office of Marketing and Communications at 717-531-8606.